Venous Thromboembolism Unit, Department of Internal Medicine, Complexo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, Spain; Universidade da Coruña (UDC), A Coruña, Spain; Hospital at Home and Palliative Care Department, Complexo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, Spain.
Division of Cardiovascular Medicine and the Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT, USA.
Interv Cardiol Clin. 2024 Oct;13(4):561-575. doi: 10.1016/j.iccl.2024.07.004. Epub 2024 Aug 13.
Catheter-based interventions and surgical embolectomy represent alternatives to systemic fibrinolysis for patients with high-risk pulmonary embolism (PE) or those with intermediate-high-risk PE who deteriorate hemodynamically. They are indicated when systemic fibrinolysis is contraindicated or ineffective, or if obstructive shock is imminent. Extracorporeal membrane oxygenation can be added to reperfusion therapies or used alone for severe right ventricular dysfunction and cardiogenic shock. These advanced therapies complement but do not replace anticoagulation, which remains the cornerstone in PE management. This review summarizes the evidence and shares practical recommendations for the use of anticoagulant therapy before, during, and after acute PE interventions.
经导管介入治疗和外科取栓术是高危肺栓塞(PE)或中高危 PE 患者血流动力学恶化时替代全身溶栓的方法。当全身溶栓禁忌或无效,或即将发生阻塞性休克时,应考虑使用这些方法。体外膜肺氧合可用于再灌注治疗,或单独用于严重右心功能障碍和心源性休克。这些先进的治疗方法是对抗凝治疗的补充,而不是替代,抗凝治疗仍然是 PE 管理的基石。本文综述了急性 PE 介入治疗前后抗凝治疗的证据,并提出了实用建议。